Pro and QoL Group

Patient-reported outcomes and Quality of life Working Group


For more than 25 years, it has been a tradition in the NMSG to add quality of life (QOL) endpoints to clinical trial protocols. In addition, methodological research of QOL measurement e.g. minimal important difference and response shift has also been conducted within the NMSG. QOL can be valid captured by patient-reported outcomes (PRO).  


Treatment decision making in patients with multiple myeloma (MM) is based on the balance between expected treatment efficiency and adverse events combined with patient preferences. For the past 15 years, several treatment options for the MM disease have emerged such as immunomodulation drugs (thalidomide, lenalidomide and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib) and monoclonal antibodies (elotuzumab and daratumumab). Symptomatic adverse events are included in the concept of QoL and are underreported by clinicians, whereas PROs have been found more precise and informative. Prognostic forecast of QOL can be used to build into patient decision aids supporting treatment decision making in a clinical setting.  



The aim of the NMSG patient-reported outcomes and quality of life (PRO/QOL) Working group is to investigate QOL aspects of patients with multiple myeloma. 


The NMSG PRO/QOL data group use a multidisciplinary research approach with inclusion of NMSG members with research interest in PRO/QOL in patients with MM. The group facilitate research projects from protocol writing, study conduct, data collection and analyse as well as reporting. The group use literature, registry, qualitative and quantitative research methods. Addition of PRO/QOL endpoint to upcoming NSMG clinical trials will be the in the centre of the PRO/QOL working groups activities. 


The benefits of integrating knowledge of QOL into treatment decision making in patient-centered care have been documented. Therefore, inclusion of QOL in treatment decision making in MM is an increasingly desirable clinical approach by patients and health care policy makers. Before that can be done, more  research of is needed. 

This website is a presentation of myeloma and the NMSG. The content of the website is for information exclusively. The information given on this site is not meant to and cannot replace professional counseling or treatment by a doctor. The information is not to be used for diagnosing or determining a treatment.

NMSG does not guarantee for the correctness of information of this website or websites to which referrals are made. NMSG cannot be held responsible neither directly nor indirectly for any damage or loss caused by your or a third party´s use or misuse of the website. All rights to the website and to material on the website belong to NMSG. This also applies to all written entries sent to the website. Entries, which are sent to the website, become the property of NMSG and may without limitation be used by NMSG and are treated without confidence. Any dispute that may arise regarding this website or as a consequence of using this website is to be settled according to Danish Law. NMSG is not responsible for direct, random, consequently indirect or criminal damages which may occur due to the access to or the use of the content on this website, including computer viruses, regardless of the accurateness or completeness.